Serina Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Serina Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2018 to Q3 2024.
  • Serina Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $6.7M, a 108% increase year-over-year.
  • Serina Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$3.89M, a 159% decline year-over-year.
  • Serina Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$4.92M, a 38.8% decline from 2022.
  • Serina Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$3.55M, a 447% decline from 2021.
  • Serina Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$649K, a 117% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$3.89M $6.7M +$3.48M +108% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$7.37M $9.04M +$7.29M +416% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$14.7M -$7.12M -$9.74M -372% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$4.92M -$12.5M -$11.5M -1178% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 $6.61M $3.22M +$4.1M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $2.51M $1.75M +$2.78M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$272K $2.62M +$3.28M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$3.55M -$979K -$687K -235% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$2.86M -$886K -$605K -215% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$2.26M -$1.03M -$757K -280% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$1.5M -$655K -$849K -438% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$649K -$292K -$253K -649% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$396K -$281K -$154K -121% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$242K -$270K -$164K -155% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$78K $194K +$221K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$299K -$39K -$32K -457% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$267K -$127K -$183K -327% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$84K -$106K -$396K -137% Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $312K -$27K -$11K -68.8% Jan 1, 2020 Mar 31, 2020 10-Q 2020-05-14
Q4 2019 $323K -$7K -$91K -108% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $414K $56K +$39K +229% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $375K $290K +$107K +58.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $268K -$16K -$3.25M -100% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $3.51M $84K Oct 1, 2018 Dec 31, 2018 10-K/A 2020-03-31
Q3 2018 $17K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $183K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $3.23M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.